by Ian Ingram: Complete Post through this link…
Respiratory syncytial virus vaccine indicated for adults 60 and up.
The FDA has approved the first-ever vaccine for respiratory syncytial virus (RSV)opens in a new tab or window, the agency announced on Wednesday.
Marketed under the trade name of Arexvy, the adjuvanted RSV prefusion F protein-based vaccine is specifically indicated for preventing lower respiratory tract infections in adults 60 and over.
Until now, no vaccine has existed to protect against RSV infection, a common scourge both for young children and older adults. According to data from the CDCopens in a new tab or window, an estimated 60,000 to 160,000 older adults in the U.S. are hospitalized each year due to RSV infections, and 6,000 to 10,000 deaths are associated with the highly contagious virus in this group.
